Managing skin reactions to targeted cancer therapy
Many clinicians are tempted to withhold or discontinue an EGFR inhibitor when the skin reaction appears or when they can’t control it. Yet, because the reaction correlates with…
Please share your feedback! We’re interested to learn more about your experience with American Nurse Journal.